A new plastic film, for which a patent has been applied, will protect Basf’s pharmaceutical excipient polyvinylpyrrolidone (PVP) in future even better against the penetration of atmospheric oxygen and thus against oxidation.
The US Pharmacopeia (USP), an independent institute, certified the PVP produced by Basf. At the same time, the PVP marketed by Basf was also certified for the European market in a wide-ranging GMP audit.
Under the registered trade name Kollidon, PVP is used in tablets as a binding agent and disintegrant. It makes tablets a true high-tech product as a binding agent it enables individual active ingredients of a tablet to form a homogenous entity and as a disintegrant it ensures that tablets break up in liquid and release the active ingredient quickly. A large proportion of the polyvinylpyrrolidones made by Basf goes to the pharmaceutical sector.
Boris Jenniches, global Business Management PVP at Basf, said: “With this, Basf will be able to offer its customers in the pharmaceutical industry an even higher product quality and, as a result, improved patient safety.
“Awareness of the quality of pharmaceutical ingredients has been growing steadily. Basf guarantees a consistently high product quality and in this way contributes to the success of its pharmaceutical customers.”